Newswise — July 12, 2022 – For men with moderate erectile dysfunction (ED), a noninvasive technique called low-intensity shockwave therapy (LiST) leads to significant improvement in sexual function, concludes a clinical trial in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"Our findings suggest LiST is highly effective and safe in patients with moderate vasculogenic ED," write Nikolaos Pyrgidis, MD, of Aristotle University of Thessaloniki, Greece, and colleagues. In the study, more than two-thirds of patients undergoing a 6-week course of LiST treatment had clinically meaningful improvement on a standard rating scale of sexual function and satisfaction.
LiST may provide new option for 'regenerative treatment' of moderate ED
Low-intensity shockwave therapy has emerged as a promising nonsurgical, non-drug treatment for ED. In the LiST procedure, the urologist uses a special probe to deliver low-intensity shockwaves along the penis. The goal is to stimulate new blood vessel formation (angiogenesis), leading to improved blood flow.
The new study included 70 men with blood flow-related (vasculogenic) ED. All patients had moderate ED, based on a standard questionnaire, the International Index of Erectile Function (IIEF). All men had at least a partial response to ED medications (phosphodiesterase type 5 inhibitors), which they stopped taking 1 month before and during the study.
One group of patients was randomly assigned to active treatment with LiST, 12 sessions delivered twice weekly over 6 weeks. The other group received an inactive, sham treatment. Response to LiST was assessed after 1 and 3 months, based on the erectile function score on the IIEF.
Men receiving active LiST had significant improvement in erectile function score: from 14 points (out of a possible 30) before treatment, to 19 points at 1 month, to 20 points at 3 months. By contrast, men assigned to sham LiST had little or no improvement. By 3 months, 79% of men in the active LiST group had at least a 5-point improvement in erectile function score – defined as the "minimal clinically significant difference" – compared to none in the sham LiST group.
Active LiST was also associated with significant increase in the number of patients reporting that they were able to successfully perform sexual intercourse. For both this and for the increase in erectile function score, the improvement remained significant after adjustment for initial responses.
While LiST is emerging as a new treatment alternative for ED, there is still limited evidence on its effectiveness and on which patients are most likely to benefit. European guidelines recommend LiST as a first-line treatment for patients with blood flow-related ED. The most recent AUA guidelines identify LiST as an investigational treatment; it is not yet approved for ED treatment by the US Food and Drug Administration.
The new study helps to address the gaps in LiST research by demonstrating its effectiveness in the large group of men with moderate ED. Patients with moderate ED "may be an ideal population for the application of regenerative treatment modalities in an attempt to delay ED progression," Dr. Pyrgidis and colleagues write. However, they emphasize the need for larger randomized trials including longer-term follow-up.
About Urology Practice
An Official Journal of the American Urological Association (AUA), Urology Practice focuses on clinical trends, challenges and practice applications in the four areas of Business, Health Policy, the Specialty and Patient Care. Information that can be used in everyday practice will be provided to the urology community via peer-reviewed clinical practice articles (including best practices, reviews, clinical guidelines, select clinical trials, editorials and white papers), "research letters" (brief original studies with an important clinical message), the business of the practice of urology, urology health policy issues, urology education and training, as well as content for urology care team members.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.